<?xml version="1.0" encoding="UTF-8"?>
<ref id="B29-cancers-12-00713">
 <label>29.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Schneider</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Oellerich</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Baldauf</surname>
    <given-names>H.-M.</given-names>
   </name>
   <name>
    <surname>Schwarz</surname>
    <given-names>S.-M.</given-names>
   </name>
   <name>
    <surname>Thomas</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Flick</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Bohnenberger</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Kaderali</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Stegmann</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Cremer</surname>
    <given-names>A.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia</article-title>
  <source>Nat. Med.</source>
  <year>2017</year>
  <volume>23</volume>
  <fpage>250</fpage>
  <lpage>255</lpage>
  <pub-id pub-id-type="doi">10.1038/nm.4255</pub-id>
  <pub-id pub-id-type="pmid">27991919</pub-id>
 </element-citation>
</ref>
